Ibrahim, Shirin
de Goeij, Jim N.
Nurmohamed, Nick S.
Pang, Jing
van den Bosch, Sibbeliene E.
Martens, Fabrice M. A. C.
Roeters van Lennep, Jeanine E.
Corpeleijn, Willemijn
Tumkaya, Talip
Hovingh, G. Kees
Watts, Gerald F.
Stroes, Erik S. G.
Reeskamp, Laurens F.
Article History
Accepted: 22 February 2024
First Online: 4 April 2024
Conflict of interest
: N.S. Nurmohamed is cofounder of Lipid Tools. J.E. Roeters van Lennep has received grants from the Dutch Heart Foundation (<i>Hartstichting</i>) and Netherlands Organisation for Health Research and Development (<i>ZonMw</i>) and research support from Novartis. G.K. Hovingh has received research grants from the <i>NWO</i> (Vidi No. 016.156.445), CardioVascular Research Initiative, European Union and Klinkerpad Fund, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi and The Medicines Company and speaker’s bureau and consulting fees (paid to the academic institution) from Amgen, Aegerion, Sanofi, and Regeneron until April 2019 and is part-time employed by and stockholder of Novo Nordisk A/S, Denmark since April 2019. G.F. Watts has received grants/lecturing fees/honoraria/advisory board fees from Amgen, Arrowhead, Sanofi, AstraZeneca, CRISPR Therapeutics, Esperion and Novartis. E.S.G. Stroes has received ad-board/lecturing fees (paid to the institution) from Amgen, Sanofi, Astra-Zeneca, Esperion, Daiichi Sankyo, Novo Nordisk, Ionis/Akcea and Novartis and is an Associate Editor of the <i>Netherlands Heart Journal</i>. L.F. Reeskamp is cofounder of Lipid Tools and has received a speaker’s fee from Ultragenyx. S. Ibrahim, J.N. de Goeij, J. Pang, S.E. van den Bosch, F.M.A.C. Martens, W. Corpeleijn and T. Tumkaya declare that they have no competing interests.